

NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

by postal voting in accordance with section 3 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

Submitted to Oncopeptides AB (publ) no later than Tuesday, 19 May 2020.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Oncopeptides AB (publ), Reg. No. 556596-6438 at the annual general meeting on 26 May 2020. The voting right is exercised in accordance with the below marked voting options.

Name of the shareholder	Personal identity number/registration number
Telephone number	E-mail
Place and date	
Signature	
Clarification of signature	

Instructions to vote in advance:

- Complete the shareholder information above
- Select the preferred voting options below
- Print, sign and send the form in the original to Oncopeptides AB (publ), Luntmakargatan 46, SE-111 37 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in that case, be sent to lisa.andersson@oncopeptides.com
- If the shareholder is a legal entity, a copy of a registration certificate or a corresponding document for the legal entity shall be enclosed together with the form. The same applies if the shareholder votes in advance by proxy
- Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this is included in the notice convening the meeting
- If a shareholder does not intend to exercise its voting right by way of advance voting, the form for advance voting should not be submitted

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorization documentation, shall be provided to Oncopeptides no later than Tuesday, 19 May 2020. An advance vote can be withdrawn up to and including Tuesday, 19 May 2020, by contacting Oncopeptides by e-mail to lisa.andersson@oncopeptides.com or by post to Oncopeptides AB (publ), Luntmakargatan 46, SE-111 37 Stockholm, Sweden. Thereafter, an advance vote can only be withdrawn if the shareholder is present, in person or by proxy, at the general meeting.

For complete proposals for the items on the agenda, kindly refer to the notice convening the meeting and the proposals on Oncopeptides' webpage.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual general meeting in Oncopeptides AB (publ) on Tuesday, 26 May 2020

The options below comprise, if not otherwise stated in the form, the proposals submitted by the board of directors and the nomination committee which are included in the notice convening the annual general meeting.

2. Election of chairman at the Annual General Meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination as to whether the Annual General Meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Resolutions in respect of
8a. adoption of the profit and loss statement and balance sheet and the group profit and loss statement and group balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
8b. allocation of the company's profits or losses in accordance with the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
8c. discharge of the members of the board of directors and the CEO from liability
8c.1 Per Wold-Olsen Yes <input type="checkbox"/> No <input type="checkbox"/>
8c.2 Brian Stuglik Yes <input type="checkbox"/> No <input type="checkbox"/>
8c.3 Cecilia Daun Wennborg Yes <input type="checkbox"/> No <input type="checkbox"/>
8c.4 Jarl Ulf Jungnelius Yes <input type="checkbox"/> No <input type="checkbox"/>
8c.5 Jennifer Jackson Yes <input type="checkbox"/> No <input type="checkbox"/>
8c.6 Jonas Brambeck Yes <input type="checkbox"/> No <input type="checkbox"/>
8c.7 Per Samuelsson Yes <input type="checkbox"/> No <input type="checkbox"/>
8c.8 Jakob Lindberg

Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Determination of the number of members of the Board of Directors and the number of auditors to be elected at the Annual General Meeting
9.1 Number of members of the board of directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9.2 Number of auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
10. Determination of fees to the board of directors and auditors
10.1 Fees to the board of directors Yes <input type="checkbox"/> No <input type="checkbox"/>
10.2 Fees to the auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
11. Election of the members of the Board of Directors and Chairman of the Board of Directors
11a. Per Wold-Olsen, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11b. Brian Stuglik, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11c. Jonas Brambeck, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11d. Cecilia Daun Wennborg, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11e. Jarl Ulf Jungnelius, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11f. Per Samuelsson, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11g. Jennifer Jackson, re-election Yes <input type="checkbox"/> No <input type="checkbox"/>
11h. Chairman of the Boards of Directors Per Wold-Olsen Yes <input type="checkbox"/> No <input type="checkbox"/>
12. Election of auditor Yes <input type="checkbox"/> No <input type="checkbox"/>
13. Resolution on guidelines for remuneration to senior management

Yes <input type="checkbox"/> No <input type="checkbox"/>
14. Resolution on new articles of association Yes <input type="checkbox"/> No <input type="checkbox"/>
15. Resolution on the introduction of a long term performance based incentive program for certain members of the Board of Directors
15a. Proposal for resolution on adoption of a long term performance based incentive program for certain members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
15b. Proposal regarding issue of warrants Yes <input type="checkbox"/> No <input type="checkbox"/>
15c. Equity swap agreement with a third party Yes <input type="checkbox"/> No <input type="checkbox"/>
16. Resolution regarding authorization for the Board of Directors to resolve upon issues of shares, warrants and/or convertibles;
16a. Main proposal Yes <input type="checkbox"/> No <input type="checkbox"/>
16b. Alternative proposal Yes <input type="checkbox"/> No <input type="checkbox"/>